2017 NCCN Annual Conference
Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment
Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the evidence for using neoadjuvant and adjuvant systemic therapies in resectable and borderline resect...
Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses selecting first- and second-line therapies for patients with advanced bladder cancer and the emerging data and role of immune checkpoi...
Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies
Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or...
Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer
Paul M. Cinciripini, PhD, of The University of Texas MD Anderson Cancer Center, discusses the oncologist’s role in addressing and documenting cancer patients’ smoking and cessation attempts as well ...
David G. Pfister, MD, on HPV and Head and Neck Cancer
David G. Pfister, MD, of Memorial Sloan Kettering Cancer Center, discusses the link between human papillomavirus and oropharyngeal cancers and what is known about the effect of HPV on treatment resp...
Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer
Christina S. Chu, MD, of Fox Chase Cancer Center, discusses the link between human papillomavirus and genital cancers and what is known about the effect of HPV on treatment response and outcome.
Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines 126
Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discusses molecular abnormalities and their use in the diagnosis, risk stratification, and selection of treatment for myelofibrosis.
Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment 126
Suzanne George, MD, of Dana-Farber Cancer Institute, discusses current and emerging systemic therapies for soft-tissue sarcoma and the options for multimodality treatment.
